A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)⁺/CD141 (BDCA-3)⁺ myeloid dendritic cells in solid tumors.

ABSTRACT:

Background

Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1)⁺/CD141(BDCA-3)⁺ myeloid dendritic cells (myDC) in the tumor microenvironment are indispensable at initiating effector T-cell responses and response to ICB.

Methods

In this phase II clinical trial, anti-PD-1 ICB pretreated oligometastatic patients (tumor agnostic) underwent a leukapheresis followed by isolation of CD1c(BDCA-1)⁺/CD141(BDCA-3)⁺ myDC. Following hypofractionated stereotactic body RT (3 × 8 Gy), patients were randomized (3:1). Respectively, in arm A (immediate treatment), intratumoral (IT) ipilimumab (10 mg) and avelumab (40 mg) combined with intravenous (IV) pembrolizumab (200 mg) were administered followed by IT injection of myD

SUBMITTER: Vounckx M 

PROVIDER: S-EPMC11219623 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature